Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118123642 | 11812364 | 2 | F | 20151125 | 20160707 | 20151208 | 20160718 | EXP | IT-SA-2015SA201713 | AVENTIS | 52.00 | YR | A | F | Y | 0.00000 | 20160718 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118123642 | 11812364 | 1 | PS | CAMPATH | ALEMTUZUMAB | 1 | Subcutaneous | 30 MG CYCLIC | N | FLP4H11 | 103948 | 30 | MG | ||||||
| 118123642 | 11812364 | 2 | C | MOVICOL | POLYETHYLENE GLYCOL 3350POTASSIUM CHLORIDESODIUM BICARBONATESODIUM CHLORIDE | 1 | 0 | QD | |||||||||||
| 118123642 | 11812364 | 3 | C | CARDICOR | BISOPROLOL | 1 | 0 | 2.5 | MG | TABLET | QD | ||||||||
| 118123642 | 11812364 | 4 | C | LASIX | FUROSEMIDE | 1 | 1/2 DAILY | 0 | QD | ||||||||||
| 118123642 | 11812364 | 5 | C | TRIATEC | RAMIPRIL | 1 | DIVISIBLE TABLETS | 0 | 2.5 | MG | QD | ||||||||
| 118123642 | 11812364 | 6 | C | KCL-RETARD | POTASSIUM CHLORIDE | 1 | PROLONGED RELEASE TABLETS | 0 | 600 | MG | TABLET | QD | |||||||
| 118123642 | 11812364 | 7 | C | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Intramuscular | 0 | 125 | MG | |||||||||
| 118123642 | 11812364 | 8 | C | EPOETIN ZETA | ERYTHROPOIETIN | 1 | 0 | 40000 | IU | /wk | |||||||||
| 118123642 | 11812364 | 9 | C | LAMIVUDINE. | LAMIVUDINE | 1 | 0 | 100 | MG | QD | |||||||||
| 118123642 | 11812364 | 10 | C | ONDANSETRON HYDROCHLORIDE. | ONDANSETRON HYDROCHLORIDE | 1 | 0 | 8 | MG | ||||||||||
| 118123642 | 11812364 | 11 | C | ALLOPURINOL. | ALLOPURINOL | 1 | 0 | 300 | MG | QD | |||||||||
| 118123642 | 11812364 | 12 | C | GLICLAZIDE | GLICLAZIDE | 1 | 0 | 30 | MG | QD | |||||||||
| 118123642 | 11812364 | 13 | C | CHLORHEXIDINE | CHLORHEXIDINE | 1 | MOUTHWASH | 0 | TID | ||||||||||
| 118123642 | 11812364 | 14 | C | NYSTATIN. | NYSTATIN | 1 | 0 | TID | |||||||||||
| 118123642 | 11812364 | 15 | C | MERITENE | 2 | 0 | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118123642 | 11812364 | 1 | Chronic lymphocytic leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118123642 | 11812364 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118123642 | 11812364 | Disease progression | |
| 118123642 | 11812364 | Lymphadenopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118123642 | 11812364 | 1 | 20151021 | 20151123 | 0 |